Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Wouter J. Kikkert"'
Autor:
Dongfeng Zhang, Xiantao Song, Sergio Raposeiras-Roubín, Emad Abu-Assi, Jose Paulo Simao Henriques, Fabrizio D’Ascenzo, Jorge Saucedo, José Ramón González-Juanatey, Stephen B. Wilton, Wouter J. Kikkert, Iván Nuñez-Gil, Albert Ariza-Sole, Dimitrios Alexopoulos, Christoph Liebetrau, Tetsuma Kawaji, Claudio Moretti, Zenon Huczek, Shaoping Nie, Toshiharu Fujii, Luis Correia, Masa-aki Kawashiri, Danielle Southern, Oliver Kalpak
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 12 (2021)
Background: Treatment of acute myocardial infarction (AMI) patients with prior stroke is a common clinical dilemma. Currently, the application of optimal medical therapy (OMT) and its impact on clinical outcomes are not clear in this patient populati
Externí odkaz:
https://doaj.org/article/1ed66cc14044431b9d2c3eb3e54f796c
Autor:
Niels MR van der Sangen, I Tarik Küçük, Jurriën M ten Berg, Marcel AM Beijk, Ronak Delewi, Alexander W den Hartog, Yolande Appelman, Niels JW Verouden, Wouter J Kikkert, José PS Henriques, Bimmer EPM Claessen
Publikováno v:
van der Sangen, N M R, Küçük, I T, ten Berg, J M, Beijk, M A M, Delewi, R, den Hartog, A W, Appelman, Y, Verouden, N J W, Kikkert, W J, Henriques, J P S & Claessen, B E PM 2022, ' P2Y12-inhibitor monotherapy after coronary stenting : are all P2Y12-inhibitors equal? ', Expert Review of Cardiovascular Therapy, vol. 20, no. 8, pp. 637-645 . https://doi.org/10.1080/14779072.2022.2104248
Introduction: P2Y(12)-inhibitor monotherapy following 1-3 months of dual antiplatelet therapy (DAPT) reduces (major) bleeding without an apparent increase in ischemic events and has therefore emerged as an alternative to 6-12 months of DAPT following
Autor:
Niels Mr, van der Sangen, I Tarik, Küçük, Jurriën M, Ten Berg, Marcel Am, Beijk, Ronak, Delewi, Alexander W, den Hartog, Yolande, Appelman, Niels Jw, Verouden, Wouter J, Kikkert, José Ps, Henriques, Bimmer Epm, Claessen
Publikováno v:
Expert review of cardiovascular therapy. 20(8)
P2YThis review critically appraises the evidence for P2YP2Y
Autor:
Dongfeng Zhang, Zenon Huczek, Oliver Kalpak, Wouter J. Kikkert, José P.S. Henriques, José Ramón González-Juanatey, Fabrizio D'Ascenzo, Masa-aki Kawashiri, Shaoping Nie, Luis C. L. Correia, Claudio Moretti, Dimitrios Alexopoulos, Iván J. Núñez-Gil, Xiantao Song, Danielle A. Southern, Tetsuma Kawaji, Toshiharu Fujii, Emad Abu-Assi, Christoph Liebetrau, Stephen B. Wilton, Sergio Raposeiras-Roubín, Jorge Saucedo, Albert Ariza-Solé
Publikováno v:
International journal of cardiology, 318, 1-6. Elsevier Ireland Ltd
Background: Acute myocardial infarction (AMI) recurrence is still high despite great progress in secondary prevention. Patients with recurrent AMI suffer worse prognosis compared to those with first AMI. The objective was to evaluate the effect of op
Autor:
Niels M R van der Sangen, Jaouad Azzahhafi, Dean R P P Chan Pin Yin, Joyce Peper, Senna Rayhi, Ronald J Walhout, Melvyn Tjon Joe Gin, Deborah M Nicastia, Jorina Langerveld, Georgios J Vlachojannis, Rutger J van Bommel, Yolande Appelman, José P S Henriques, Jurriën M ten Berg, Wouter J Kikkert
Publikováno v:
Open Heart, 9(1):001984. BMJ Publishing Group
Open Heart, 9(1):e001984. BMJ Publishing Group
van der Sangen, N M R, Azzahhafi, J, Chan Pin Yin, D R P P, Peper, J, Rayhi, S, Walhout, R J, Tjon Joe Gin, M, Nicastia, D M, Langerveld, J, Vlachojannis, G J, van Bommel, R J, Appelman, Y, Henriques, J P S, ten Berg, J M & Kikkert, W J 2022, ' External validation of the GRACE risk score and the risk-treatment paradox in patients with acute coronary syndrome ', Open Heart, vol. 9, no. 1, e001984 . https://doi.org/10.1136/openhrt-2022-001984
Open heart, 9(1):e001984. BMJ Publishing Group
Open Heart, 9(1):e001984. BMJ Publishing Group
van der Sangen, N M R, Azzahhafi, J, Chan Pin Yin, D R P P, Peper, J, Rayhi, S, Walhout, R J, Tjon Joe Gin, M, Nicastia, D M, Langerveld, J, Vlachojannis, G J, van Bommel, R J, Appelman, Y, Henriques, J P S, ten Berg, J M & Kikkert, W J 2022, ' External validation of the GRACE risk score and the risk-treatment paradox in patients with acute coronary syndrome ', Open Heart, vol. 9, no. 1, e001984 . https://doi.org/10.1136/openhrt-2022-001984
Open heart, 9(1):e001984. BMJ Publishing Group
ObjectivesTo validate the Global Registry of Acute Coronary Events (GRACE) risk score and examine the extent and impact of the risk–treatment paradox in contemporary patients with acute coronary syndrome (ACS).MethodsData from 5015 patients with AC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1ddac85cd034dae78172370f78de4e3
https://cris.maastrichtuniversity.nl/en/publications/afb8beb5-f92a-4933-a8ba-f89ed6655107
https://cris.maastrichtuniversity.nl/en/publications/afb8beb5-f92a-4933-a8ba-f89ed6655107
Autor:
José Ramón González-Juanatey, Andrés Íñiguez-Romo, Sergio Raposeiras-Roubín, Jing-Yao Fan, Zenon Huczek, Yan Yan, Berenice Caneiro Queija, María Cespón Fernández, José María García-Acuña, María Castiñeira-Busto, Fabrizio D'Ascenzo, Jorge F. Saucedo, Toshiharu Fujii, José P.S. Henriques, Kenji Sakata, Masakazu Yamagishi, Wouter J. Kikkert, Sasko Kedev, Emad Abu-Assi, Luis C. L. Correia, Danielle A. Southern, Stephen B. Wilton, Tetsuma Kawaji, Dimitrios Alexopoulos, Masa-aki Kawashiri, Krzysztof J. Filipiak, Claudio Moretti, Cristina Barreiro Pardal, Yuji Ikari, Yalei Chen, Xiao Wang, Elena López Rodríguez, Takuya Nakahayshi, Isabel Muñoz-Pousa, Xiantao Song, Ioanna Xanthopoulou, Michal Kowara, Belén Terol, Fiorenzo Gaita, Albert Ariza-Solé, Shaoping Nie, Neriman Osman, Iván J. Núñez-Gil, Hiroki Shiomi, Dongfeng Zhang, Rafael Cobas Paz, Alberto Garay, Helge Möllmann, Christoph Liebetrau
Publikováno v:
European heart journal. Acute cardiovascular care, 9(7), 764-770. SAGE Publications Ltd
Background: The rate of intracranial haemorrhage after an acute coronary syndrome has been studied in detail in the era of thrombolysis; however, in the contemporary era of percutaneous coronary intervention, most of the data have been derived from c
The risk-treatment paradox in acute coronary syndrome patients: insights from the FORCE-ACS registry
Autor:
J P Simao Henriques, J. M. ten Berg, Wouter J. Kikkert, Jaouad Azzahhafi, Force-Acs, N M R Van Der Sangen, D R P P Chan Pin Yin
Publikováno v:
European Heart Journal. 42
Background Acute coronary syndrome (ACS) patients at high risk might benefit most from guideline-recommended interventions. However, it is well recognized that the delivery of guideline-directed care is inversely related to the estimated mortality ri
Autor:
Stefan G. J. Leuven, Michelle M. de Leau, Nick D. Fagel, Wouter J. Kikkert, Loek van Heerebeek, Robert K. Riezebos
Publikováno v:
Journal of Clinical Medicine
Volume 10
Issue 16
Journal of clinical medicine, 10(16):3636. Multidisciplinary Digital Publishing Institute (MDPI)
Journal of Clinical Medicine, Vol 10, Iss 3636, p 3636 (2021)
Volume 10
Issue 16
Journal of clinical medicine, 10(16):3636. Multidisciplinary Digital Publishing Institute (MDPI)
Journal of Clinical Medicine, Vol 10, Iss 3636, p 3636 (2021)
The timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) remains a matter of debate. The relationship between the timing of invasive management and left ventricular function (LVF) is largely unknown. The
Publikováno v:
Heart international. 15(2)
The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened
Autor:
Marije M. Vis, Bimmer E. Claessen, Ho Yee Cheung, Jorrit S. Lemkes, Niels J.W. Verouden, Wouter J. Kikkert, José P.S. Henriques, Paul Knaapen, Alexander Nap, Yolande Appelman, Ronak Delewi, Marcel A.M. Beijk, Niels M R van der Sangen
Publikováno v:
Journal of Clinical Medicine
Volume 10
Issue 13
Journal of Clinical Medicine, 10(13)
Journal of clinical medicine, 10(13):2829. Multidisciplinary Digital Publishing Institute (MDPI)
Journal of Clinical Medicine, Vol 10, Iss 2829, p 2829 (2021)
van der Sangen, N M R, Cheung, H Y, Verouden, N J W, Appelman, Y, Beijk, M A M, Claessen, B E P M, Delewi, R, Knaapen, P, Lemkes, J S, Nap, A, Vis, M M, Kikkert, W J & Henriques, J P S 2021, ' Cangrelor use in routine practice: a two-center experience ', Journal of Clinical Medicine, vol. 10, no. 13 . https://doi.org/10.3390/jcm10132829
Volume 10
Issue 13
Journal of Clinical Medicine, 10(13)
Journal of clinical medicine, 10(13):2829. Multidisciplinary Digital Publishing Institute (MDPI)
Journal of Clinical Medicine, Vol 10, Iss 2829, p 2829 (2021)
van der Sangen, N M R, Cheung, H Y, Verouden, N J W, Appelman, Y, Beijk, M A M, Claessen, B E P M, Delewi, R, Knaapen, P, Lemkes, J S, Nap, A, Vis, M M, Kikkert, W J & Henriques, J P S 2021, ' Cangrelor use in routine practice: a two-center experience ', Journal of Clinical Medicine, vol. 10, no. 13 . https://doi.org/10.3390/jcm10132829
Cangrelor is the first and only intravenous P2Y12-inhibitor and is indicated when (timely) administration of an oral P2Y12 inhibitor is not feasible in patients undergoing percutaneous coronary intervention (PCI). Our study evaluated the first years